CARDIOVASCULAR DISEASE TREATMENT AND PREVENTION
First Claim
1. A method, comprising:
- administering, to the skin of a subject having or at risk of atherosclerosis, a composition comprising an effective amount of gonadotropin-releasing hormone (GnRH) and nitric oxide to treat or prevent atherosclerosis, and a carrier having a phosphatidylcholine component entrapping the nitric oxide.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
14 Citations
128 Claims
-
1. A method, comprising:
administering, to the skin of a subject having or at risk of atherosclerosis, a composition comprising an effective amount of gonadotropin-releasing hormone (GnRH) and nitric oxide to treat or prevent atherosclerosis, and a carrier having a phosphatidylcholine component entrapping the nitric oxide. - View Dependent Claims (3, 4, 5, 6, 7, 12, 13, 14, 15, 35, 36, 50, 54)
-
2. (canceled)
-
8-11. -11. (canceled)
-
16-30. -30. (canceled)
-
31. A method, comprising contacting the skin of a subject having or at risk for atherosclerosis and/or hypertension with a composition comprising:
an emulsion comprising a first phase comprising gonadotropin-releasing hormone (GnRH), nitric oxide, and lecithin, and a second phase comprising an emulsifier, wherein the lecithin is present at least about 0.25% by weight of the composition, and wherein the first phase comprises no more than about 250 ppm of water by weight of the composition. - View Dependent Claims (32, 33)
-
34. (canceled)
-
37-49. -49. (canceled)
-
51-53. -53. (canceled)
-
55-126. -126. (canceled)
-
127. A method, comprising:
administering, to the skin of a subject having or at risk of atherosclerosis, a composition comprising an effective amount of gonadotropin-releasing hormone (GnRH) to treat or prevent atherosclerosis.
-
128-282. -282. (canceled)
Specification